Inhibition of autism spectrum disorder using ribosomal read-through compounds
AssigneeFriedrich Miescher Inst. for Biomedical Research
InventorsMarc BUEHLER, Veronica OSTAPCUK
Life of this patent
Estimating the term…
Abstract
The present invention relates to the novel use of read-through compounds for use in the treatment and/or prevention of Autism Spectrum Disorder.
Claims8
A compound promoting ribosomal read-through of premature stop codons, said compound being selected from the group comprising gentamicin, streptomycin, amikacin, kanamycin, tobramycin, netilmicin, neomycin, framycetin, negamycin, paromomycin, hygromycin B, apramycin, dihydrostreptomycin, sisomicin, erythromycin, NPC-14 (arbekacin), ELX-02, G-418, ribostamycin, bekanamycin, dibekacin, spectinomycin and derivatives and analogs thereof, for use in the prevention and/or treatment of Autism Spectrum Disorder (ASD).
A compound promoting ribosomal read-through of premature stop codons, said compound being selected from the group comprising chloramphenicol, azidamfenicol, thiamphenicol and florfenicol and derivatives or analogs thereof for use in the prevention and/or treatment of Autism Spectrum Disorder (ASD).
A compound promoting ribosomal read-through of premature stop codons, said compound being selected from the group comprising linezolid, eperzolid, posizolid, radezolid, ranbezolid, sutezolid, tedizolid and analogs or derivatives thereof for use in the prevention and/or treatment of Autism Spectrum Disorder (ASD).
A compound promoting ribosomal read-through of premature stop codons, said compound being selected from the group comprising PTC124 (ataluren), RTC 13, RTC 14, amlexanox and tylosin for use in the prevention and/or treatment of Autism Spectrum Disorder (ASD).
The compound for use according to any of the preceding claims wherein the Autism Spectrum Disorder (ASD) is Helsmoortel-van der Aa syndrome.
Dependencies are inferred from the claim text.